Article Text

other Versions

PDF
Expression of PTEN and its pseudogene PTENP1, and promoter methylation of PTEN in non-tumourous thymus and thymic tumours
  1. Atsuko Masunaga1,
  2. Mutsuko Omatsu2,
  3. Toshiaki Kunimura2,
  4. Shugo Uematsu1,
  5. Yoshito Kamio3,
  6. Akihiko Kitami1,
  7. Yohei Miyagi4,
  8. Kenzo Hiroshima5,
  9. Takashi Suzuki1
  1. 1Respiratory Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
  2. 2Department of Clinicodiagnostic Pathology, Showa University Northern Yokohama Hospital, Yokohama, Japan
  3. 3Department of Emergency Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan
  4. 4Molecular Pathology & Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan
  5. 5Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan
  1. Correspondence to Dr A Masunaga, Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Centre, 477-96 Owada-Shinden, Yachiyo-shi, Chiba 276-8524, Japan; nonkoamesho0324{at}yahoo.co.jp

Abstract

Aims Mutation or promoter methylation of the phosphatase tensin homologue deleted on chromosome 10 tumour suppressor gene (PTEN) promotes some cancers. Moreover, PTENP1 (PTEN pseudogene) transcript regulates PTEN expression and is thought to be associated with tumourigenesis in some cancers. Here, we investigated PTEN expression in thymic epithelium and thymic epithelial tumours.

Methods Immunohistochemical analysis of PTEN was performed on two non-tumourous thymus (NT) samples, 33 thymomas (three type A, eight type AB, 11 type B1, six type B2, and five type B3), and four thymic carcinomas (TCs). In 16 cases (two NT, three A, five B1, two B2, one B3 and three TC), analyses of mutations, promoter methylation and comparisons of PTEN mRNA and PTENP1 transcripts were undertaken using PCR-direct sequencing, methylation-specific PCR, and reverse-transcription real-time PCR after target cell collection with laser microdissection.

Results PTEN protein was not immunohistochemically detected in NT epithelium or types B1 or B2 thymoma cells, but was expressed in type A thymoma and carcinoma cells. Neither PTEN mutations nor promoter methylation were detected in any samples. Statistical analysis revealed that PTEN mRNA expression was highest in NT epithelium and lowest in type A thymoma cells. PTENP1 transcript expression did not significantly differ among NT, thymoma and TC samples.

Conclusions We speculated that NT epithelium and types B1/B2 thymoma cells have a mechanism of PTEN translation repression and/or acceleration of protein degradation, whereas type A thymoma cells exhibit transcriptional repression of PTEN mRNA and accelerated translation and/or protein accumulation.

  • CANCER
  • HISTOPATHOLOGY
  • IMMUNOCYTOCHEMISTRY
  • MOLECULAR PATHOLOGY
  • TUMOUR BIOLOGY

Statistics from Altmetric.com

Footnotes

  • Handling editor Runjan Chetty

  • Contributors AM: histological diagnosis of all materials, microdissection, isolation of nucleic acid, design of PCR primers, real-time PCR, statistical analysis and recapitulation. MO and TK: histological diagnosis of all materials. SU, YK and AK: obtaining surgical samples and statistical analysis. YM: design of PCR primers and technical advice for molecular analyses. KH: histological diagnosis, statistical analysis and draft editing. TS: obtaining surgical samples, statistical analysis and recapitulation.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval The Ethics Committee of the Human Genome and Genetic Analysis of Showa University (registration number 235).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.